Igor Matushansky
Director/Board Member chez Crescendo Biologics Ltd.
Profil
Igor Matushansky is currently a Non-Executive Director at Crescendo Biologics Ltd.
and an Assistant Professor at The Trustees of Columbia University in The City of New York.
He previously worked as the Global Head of Clinical & Scientific Development at Novartis Corp.
from 2012 to 2015, a Professor at Columbia University Medical Center from 2007 to 2012, the Global Head of Translational Development at Daiichi Sankyo, Inc. from 2015 to 2017, and the Chief Medical Officer & Global Head of Research at HOOKIPA Pharma, Inc. from 2017 to 2022.
He received his undergraduate degree from The Trustees of Columbia University in The City of New York and his doctorate from Albert Einstein College of Medicine, Inc.
Postes actifs de Igor Matushansky
| Sociétés | Poste | Début |
|---|---|---|
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 02/07/2018 |
| The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | - |
Anciens postes connus de Igor Matushansky
| Sociétés | Poste | Fin |
|---|---|---|
| HOOKIPA PHARMA INC. | Chief Tech/Sci/R&D Officer | 30/06/2022 |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Corporate Officer/Principal | 01/01/2017 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2015 |
| Columbia University Medical Center | Corporate Officer/Principal | 01/01/2012 |
Formation de Igor Matushansky
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HOOKIPA PHARMA INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
